Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery

作者：Lynn Legg, Russel Tilney, Cheng‐Fang Hsieh, Simiao Wu, Erik Lundström, Ann‐Sofie Rudberg, Mansur A. Kutlubaev, Martin Dennis, Babak Soleimani, Amanda Barugh, Maree L. Hackett, Graeme J. Hankey, Gillian Mead · 发表于：Cochrane Database of Systematic Reviews · 年份：2019 · DOI：10.1002/14651858.cd009286.pub3 · 被引用次数：73 · 研究领域：Stroke Rehabilitation and Recovery、Acute Ischemic Stroke Management、Cardiac Health and Mental Health

BACKGROUND: Stroke is a major cause of adult disability. Selective serotonin reuptake inhibitors (SSRIs) have been used for many years to manage depression and other mood disorders after stroke. The 2012 Cochrane Review of SSRIs for stroke recovery demonstrated positive effects on recovery, even in people who were not depressed at randomisation. A large trial of fluoxetine for stroke recovery (fluoxetine versus placebo under supervision) has recently been published, and it is now appropriate to update the evidence. OBJECTIVES: To determine if SSRIs are more effective than placebo or usual care at improving outcomes in people less than 12 months post-stroke, and to determine whether treatment with SSRIs is associated with adverse effects. SEARCH METHODS: For this update, we searched the Cochrane Stroke Group Trials Register (last searched 16 July 2018), the Cochrane Controlled Trials Register (CENTRAL, Issue 7 of 12, July 2018), MEDLINE (1946 to July 2018), Embase (1974 to July 2018), CINAHL (1982 July 2018), PsycINFO (1985 to July 2018), AMED (1985 to July 2018), and PsycBITE March 2012 to July 2018). We also searched grey literature and clinical trials registers. SELECTION CRITERIA: We included randomised controlled trials (RCTs) that recruited ischaemic or haemorrhagic stroke survivors at any time within the first year. The intervention was any SSRI, given at any dose, for any period, and for any indication. We excluded drugs with mixed pharmacological effects. The comparat...